argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-11-11 08:37 |
arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Rel…
|
English | 470.1 KB | ||
| 2014-11-03 08:34 |
arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Wa…
|
English | 21.1 KB | ||
| 2014-10-15 08:21 |
arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive…
|
English | 167.7 KB | ||
| 2014-09-18 07:19 |
arGEN-X completes recruitment of first cohort of 15 patients with CD70-positive…
|
English | 166.0 KB | ||
| 2014-09-17 07:38 |
arGEN-X' core patents protecting lead clinical candidates ARGX-110 and ARGX-111…
|
English | 167.6 KB | ||
| 2014-09-15 09:17 |
arGEN-X appoints Petercam NV as Liquidity Provider to facilitate trading on Eur…
|
English | 161.2 KB | ||
| 2014-08-27 08:31 |
arGEN-X - Business Update and First Half 2014 Results
|
English | 542.4 KB | ||
| 2014-08-21 08:40 |
arGEN-X: Notice of Results for the First Half 2014 and Business Update
|
English | 147.3 KB | ||
| 2014-08-19 14:32 |
arGEN-X announces positive preclinical results for ARGX-113
|
English | 471.0 KB | ||
| 2014-08-11 10:48 |
arGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option an…
|
English | 367.4 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
